Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.
A method was developed and validated for the analysis of R(-)-apomorphine, (R-)-apocodeine and R(-)-norapomorphine in human plasma and urine with N-propylnorapomorphine as internal standard using gas chromatography/mass spectrometry (GC/MS) and single-ion monitoring after a single liquid-liquid extraction and silylation of compounds. The quantification limits were 1 ng/ml for apomorphine and apocodeine and 25 ng/ml for norapomorphine. Calibration curves were linear, within the range 1-100 ng/ml. Variation in intraday and interday precision was below 10%. This method was applied to study apomorphine bioavailability in nine patients with Parkinson's disease before and after coadministration of a catechol-O-methyl transferase inhibitor.
Libert
Frédéric
F
Pharmacology and Toxicology Laboratory, CHU G. Montpied, Clermont-Ferrand, France.
Coudoré
François
F
Richard
Damien
D
Durif
Franck
F
Eschalier
Alain
A
D001058:Apomorphine / Q000031:analogs & derivatives* / Q000032:analysis* / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000627:therapeutic use; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D006801:Humans; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy; D015203:Reproducibility of Results
D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D009570:Nitriles; C008668:norapomorphine; C071192:entacapone; D001058:Apomorphine; C006613:apocodeine